Purinergic–Glycinergic Interaction in Neurodegenerative and Neuroinflammatory Disorders of the Retina

Laszlo G. Harsing, Jr. 1,*, Gábor Szénási 2, Tibor Zelles 1,3 and László Köles 1,3

1 Department of Pharmacology and Pharmacotherapy, Semmelweis University, H-1089 Budapest, Hungary; zelles.tibor@med.semmelweis-univ.hu (T.Z.); koles.laszlo@med.semmelweis-univ.hu (L.K.)
2 Institute of Translational Medicine, Semmelweis University, H-1089 Budapest, Hungary; szenasi.gabor@med.semmelweis-univ.hu
3 Department of Oral Biology, Semmelweis University, H-1089 Budapest, Hungary
4 Correspondence: harsing.laszlo@med.semmelweis-univ.hu; Tel.: +36-1-210-4416

Abstract: Neurodegenerative–neuroinflammatory disorders of the retina seriously hamper human vision. In searching for key factors that contribute to the development of these pathologies, we considered potential interactions among purinergic neuromodulation, glycinergic neurotransmission, and microglia activity in the retina. Energy deprivation at cellular levels is mainly due to impaired blood circulation leading to increased release of ATP and adenosine as well as glutamate and glycine. Interactions between these modulators and neurotransmitters are manifold. First, P2Y purinoceptor agonists facilitate reuptake of glycine by glycine transporter 1, while its inhibitors reduce reverse-mode operation; these events may lower extracellular glycine levels. The consequential changes in extracellular glycine concentration can lead to parallel changes in the activity of NR1/NR2B type NMDA receptors of which glycine is a mandatory agonist, and thereby may reduce neurodegenerative events in the retina. Second, P2Y purinoceptor agonists and glycine transporter 1 inhibitors may indirectly inhibit microglia activity by decreasing neuronal or glial glycine release in energy-compromised retina. These inhibitions may have a role in microglia activation, which is present during development and progression of neurodegenerative disorders such as glaucomatous and diabetic retinopathies and age-related macular degeneration or loss of retinal neurons caused by thromboembolic events. We have hypothesized that glycine transporter 1 inhibitors and P2Y purinoceptor agonists may have therapeutic importance in neurodegenerative–neuroinflammatory disorders of the retina by decreasing NR1/NR2B NMDA receptor activity and production and release of a series of proinflammatory cytokines from microglial cells.

Keywords: retina; purinergic modulation; glycinergic neurotransmission; microglia; neuroinflammation; neurodegeneration; glycine transporters

1. Introduction

Neurodegenerative disorders occur with a high incidence in the elderly. These pathologies affect the motor system in Parkinson’s or Huntington’s diseases, memory in Alzheimer’s disease, or other additional critically important neural functions after impairments in cerebral blood circulation. The retina, which is commonly considered as an outside part of the central nervous system, is also affected by neurodegenerative disorders. Most of them may lead to loss of neurons in the retinal circuitry and consecutive impaired vision or blindness. Among the neurodegenerative diseases, we mention retinal hypoxia/ischemia, glaucomatous and diabetic neuropathies, and age-related macular degeneration and those that appear less frequently, such as human recessive retinitis pigmentosa or inherited photoreceptor degeneration. These disorders may occur as a sudden pathological event or show a progressively declining clinical course, but vision may be seriously hampered or lost in all disorders. Despite different clinical symptoms, there are
a number of common factors in their pathogenesis, like neuroinflammation associated with neurodegeneration. Retinal hypoxia, as a persisting insult, may induce enhanced purinergic modulation and glutamatergic–glycinergic neurotransmission. Activation of the two systems may evoke sustained release of inflammatory mediators from activated microglia and the resultant chronic proinflammatory environment may induce development or exacerbation of retinal neurodegenerative disorders. There are several excellent review articles published on different aspects of the neurodegenerative pathologies of the retina [1–3].

In spite of the extended research effort, the currently used therapeutics only slow down the progression of retinal neurodegenerative disorders, whereas normalization of impaired visual functions can be rarely achieved. It is, therefore, mandatory to develop novel therapeutic interventions. This goal, however, cannot be reached without unfolding the pathophysiology of retinal neurodegenerative diseases. The aim of this review is to highlight a possible interaction between purinergic and glycinergic signaling systems in neuroinflammatory–neurodegenerative disorders of the retina. This interaction is, however, further complicated by the findings that microglia, the resident immune cells of the central nervous system and retina, are involved not only in neuronal cell destructions but also in compensatory neural repair following insulting influences [4,5].

2. Neural Circuitries and Glial Cell Types in the Retina

Figure 1A shows the cell types and the organization of neural circuitry after hematoxylin-eosin staining of the retina [6]. The vertical section of the retina showed the retinal pigment epithelium (PRE) as the outermost layer followed by the photoreceptor layer (PRL) and outer nuclear layer (ONL), the latter containing the cell bodies of the cone and rod photoreceptors. The neurotransmitter in photoreceptors is glutamate, the release of which decreases to light exposition of the retina. The second-degree neurons in the retina are glutamatergic bipolar cells. The cell bodies of the ON and OFF cone bipolar cells and the connecting ganglion cells form the inner nuclear layer (INL) and the ganglion cell layer (GCL) of the retina, respectively. The inner nuclear layer also contains amacrine cells mostly releasing glycine or GABA as neurotransmitters, which, together with the horizontal cells, compose the horizontal visual pathway [7]. Neuronal connection, which transmits signals from rod bipolar cells to cone bipolar cells, is established by the AII cell, a specific type of glycinergetic amacrine cell [8]. The outer and inner plexiform layers (OPL, IPL) contain the synaptic connections between the photoreceptors and bipolar cells and the bipolar cells and retinal ganglion cells, respectively (Figure 1B). These layers show characteristic alterations or tapering in various neurodegenerative disorders or injuries of the retina [9,10].
Besides the neural circuits, the retina also contains numerous glia cells termed macroglia (Müller cells and astrocytes) and microglial cells. The principal macroglia Müller cells span all retinal layers, whereas astrocytes are mostly located close to the nerve fiber layer and the ganglion cell layer [3,7,12]. Müller cells are the major source of adenosine triphosphate (ATP) released into the extracellular space, which then modulates both neural and microglial cell activities [7,13]. Müller cells express glycine transporter 1 (GlyT-1), which regulates extracellular glycine concentrations in the retina following its release from macroglia and amacrine cells [14,15]. The glial marker, glial fibrillary acidic protein (GFAP), is expressed in both Müller glia cells and astrocytes [13,16,17].

The other major type of retinal glia cell is microglia. They originate from macrophage or monocyte precursors and are considered as the major immunocompetent cell type of the retina [18]. In healthy retina, microglia cells are characterized by small somata and extensively ramified processes at rest [3]. Microglial cells, which exhibit different morphologies in the retina, are mainly present in the inner and outer plexiform layers, ganglion cell layer, and nerve fiber layer (Figure 1C) [7,11,19,20].
3. Cellular Biology of Microglia in Neural and Retinal Tissues

Microglia are the resident immune cells of the central nervous system as well as the retina. Microglia exist in different forms. Resting microglia are derived from macrophage-like cells and they can be characterized by small cell bodies and multiple branched processes arising from the cell bodies with down-regulated macrophage-like properties [21]. Microglia processes exhibit continuous movements controlling the immunological environment (surveillance mode) in order to detect signals from stressed neurons or macroglia. Microglial cells also have a function in normal retinal growth, neurogenesis, and retinal blood vessel formation under physiological conditions.

The shape of microglial cells turns to be amoeboid during microglial activation in retinopathological events and cellular hypertrophy and process retraction can be also observed [22]. The amoeboid form of microglia is enlarged in size, and microglia occur either as single cells or in clusters and their phagocytic activity is enhanced [3]. In response to pathogenic signals such as ischemia or oxidative stress, microglia proliferate and migrate towards the site of tissue injury [23]. Pathological stimuli also activate macroglial cells and cause gliosis of the retina. The gliosis of Müller cells is characterized by cellular hypertrophy, proliferation, and upregulation of GFAP expression [13].

Ramified microglia is a model of resting-like cells, whereas addition of the bacterial cell wall component lipopolysaccharide (LPS) induces activation of microglial cells. This procedure is also called a shift of microglia from an ineffective to an effective (activated) state. Stimulation with LPS is accompanied by altered K+ channel expression: Resting microglial cells do not express voltage-activated K+ channels, their expression together with P2Y purinoceptors can be observed following microglia activation [24].

Microglial cells undergo two kinds of activation in response to infection, tissue traumatic or hypoxic injury [10, 25]. These two types are designated as M1 and M2 microglial cells, which are also mentioned in the literature as proinflammatory and anti-inflammatory phenotypes [26]. The M1 first state is a neurotoxic phenotype that is characterized with massive inflammatory responses, release of tumor necrosis factor α (TNFα) and other neurotoxic inflammatory mediators/cytokines such as interleukin (IL)-1α, IL-1β, IL-6, and IL-12 [3]. Release of TNFα and IL-6 from microglial cells is toxic and induces neuronal cell death [27]. In certain circumstances, the M1 state may turn to uncontrolled activation of microglial cells, leading to a chronic inflammation in neural tissues. The increased production of the various proinflammatory cytokines may maintain an inflammatory condition and sustained release of these factors also contributes to neuronal cell death [28].

The second microglia phenotype is M2, which can secrete a series of anti-inflammatory mediators (IL-4, IL-10, IL-13, TGF-1β), and neurotrophic factors such as insulin-like growth factor 1 (IGF-1). M2 microglia serve inflammation resolution and promote neuroprotection and neuronal survival [29]. M2 microglia were recognized as neuroprotective in neurodegenerative diseases preventing neuroinflammation both in the brain and in the retina. M2 microglia downregulate inflammatory cells and the released protective and trophic factors induce immunosuppressive responses [30]. During M1 to M2 transition, the acute and prolonged phases of microglia activation may represent a dual role of these cells in neuroinflammatory and neurodegenerative disorders of the retina [26]. Chronic neuroinflammation in neural or retinal tissues may be due to lack of sufficient M2 microglia responses either because of a lower number of microglial cells or a lower secretion of neuroprotective factors [30]. It has been suggested that phenotypic shift of microglia from proinflammatory M1 function to anti-inflammatory M2 function may be beneficial in retinal neurodegenerative disorders [25].

Microglia also become activated in pathological angiogenesis in the retina. Vascular endothelial growth factor (VEGF) released from microglia and monocytes has a crucial role in blood vessel growth. VEGF is also an inflammatory mediator and contributes to inflammatory responses [31]. In a mouse model of macular degeneration, VEGF is released from microglial cells into the subretinal space causing choroidal neovascularization
Increased levels of VEGF and choroidal neovascularization were reported in patients suffering from age-related macular degeneration. Elevated vitreous VEGF levels were also shown in patients with retinal vein occlusion [32]. Microglial cells can produce and the release brain-derived neurotrophic factor (BDNF) and other neurotrophic factors such as nerve growth factor (NGF), inducing trophic cascades but also cell death in developing retina [18,33,34].

4. Purinergic Modulation of Neural Tissues

Ischemia and other pathological conditions like mechanical perturbation and distension, cell swelling, stretching, or increased hydrostatic pressure all lead to ATP release [35]. ATP can be released from neurons into the extracellular space by an external Ca²⁺-dependent exocytotic mechanism evoked by membrane depolarization. Besides neurons, ATP can also be released from glia cells by Ca²⁺-dependent and independent means [4]. The release of ATP may also occur though the large transmembrane pannexins hemichannels from neurons and astrocytes [28,36].

ATP, if once released, is metabolized into ADP, AMP, and adenosine in the extracellular space by ecto-5'-nucleotidases (CD73) and ecto-nucleotide triphosphate diphosphohydrolases (NTPDases, CD39) [2,37,38]. Activity of these enzymes can be modified pharmacologically, e.g., ARL67156 is an inhibitor of NTPDases (Table 1). The turnover of the neural or glial ATP released towards the extracellular space may end up by uptake of the formed adenosine into neurons or glial cells. Adenosine reuptake inhibitors increase adenosine concentrations in the extracellular space (Table 1). Adenosine can also be produced intracellularly and effluxed from the intracellular space by adenosine transporter reversal. The mechanism commonly implicated in adenosine release involves bi-directional nucleoside transport. Thus, the Na⁺-dependent concentrative nucleoside transporters assure uptake of adenosine from the extracellular space (normal-mode operation), whereas operation of the transporter in the reverse or release-mode operation results in increased adenosine efflux from the cells [39]. The extracellular concentration of adenosine is also determined by the operation of the Na⁺-independent equilibrative nucleoside transporter [40]. Adenosine levels increase at the site of tissue damage or in the retina exposed to hypoxia and ischemia-reperfusion [41,42].

Table 1. Drugs used to investigate purinoceptors in neurodegenerative–neuroinflammatory disorders of the central nervous system and retina.

| Drugs          | Mode of Action            |
|----------------|---------------------------|
| P2 nucleotide purinoceptors |                         |
| α,β-Methylene-ATP | P2 agonist                |
| PPADS         | P2 antagonist              |
| Suramin       | non-specific P2 antagonist |
| P2Y nucleotide purinoceptors |                     |
| 2-MeS-ATP     | P2 agonist                |
| 2-MeS-ADP     | P2Y₁,12,13 agonist        |
| MRS 2365      | P2Y₁ agonist              |
| MRS 2179      | P2Y₁ antagonist            |
| MRS 2211      | P2Y₁,12 antagonist         |
| P2X nucleotide purinoceptors |                   |
| β,γ-Methylene-ATP | P2X agonist                |
| BzATP         | P2X agonist                |
| TNP-ATP       | P2X antagonist              |
| NF449         | P2X₁ antagonist             |
| Abbreviation           | Description                                                                 |
|------------------------|-----------------------------------------------------------------------------|
| R-PIA                  | A<sub>1</sub> agonist                                                       |
| CCPA                   | A<sub>1</sub> agonist                                                       |
| CPA                    | A<sub>1</sub> antagonist                                                     |
| DPCPX                  | A<sub>2</sub> agonist                                                       |
| CGS21680               | A<sub>2</sub>A antagonist                                                   |
| SCH58261               | A<sub>2</sub>A antagonist                                                   |
| ZM-241,385             | A<sub>2</sub>A antagonist                                                   |
| BAY 60-6583            | A<sub>2B</sub> agonist                                                      |
| LUF-5835               | A<sub>2B</sub> agonist                                                      |
| MRS-1706               | A<sub>2B</sub> antagonist                                                   |
| CF101                  | A<sub>3</sub> agonist                                                       |
| CP-532,903             | A<sub>3</sub> agonist                                                       |
| MRE 3008F20            | A<sub>3</sub> antagonist                                                     |
| ARL67156               | ecto-ATPase inhibitor                                                       |
| NBMPR                  | adenosine reuptake inhibitor                                                |
| ARL 67156              | 6-N,N-diethyl-D-β,γ-dibromomethylene ATP                                     |
| BAY 60-6583            | 2-[6-Amino-3,5-dicyano-4-[4-(cyclopropylmethoxy)phenyl]-2-pyridinyl]thio] acetamide |
| BzATP                  | 2′,5′-O-4-benzo-yl)-ATP                                                     |
| CCPA                   | 2-chloro-N6-cyclopentyladenosine                                           |
| CF101                  | (N6-3-iodobenzyl)-5'-N-methylcarboxamidoadenosine                           |
| CGS 21680              | 4-[2][6-amino-9-(N-ethyl-β-D-ribofuranuronamidosyl)-9H-purin-2-yl]amino[ethyl] benzenepropionic acid |
| CP-532,903             | (2S,3S,4R,5R)-3-amino-5-[6-(2,5-dichlorobenzylamino)purin-9-yl]-4 hydroxytetrahydrofuran-2-carboxylic acid methylamide |
| CPA                    | N6-cyclopentyladenosine                                                    |
| DPCPX                  | Dipropylcyclopentylxanthine                                                |
| LUF-5835               | 1-[6-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin2-yl]-N-methylpyrazole-4-carboxamide |
| 2-MeS-ATP              | 2-methylthio-ATP                                                           |
| 2-MeSADP               | 2-methylthio-ADP                                                           |
| MRE 3008F20            | N-[2-(2-Furanyl)-8-propyl-8H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin 5-yl]-N'-(4-methoxyphenyl)urea |
| MRS 1706               | N-(4-acetylphenyl)-2-[4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy]acetamide |
| MRS 2179               | N6-methyl-2′-deoxyadenosine-3′,5′-bisphosphate                              |
| MRS 2211               | pyridoxal-5′-phosphate-6-azo(2-chloro-5-nitrophenyl)2,4-disulfonate          |
| MRS 2365               | [(1R,2R,3S,4R,5S)-4-[6-amino-2-(methylthio)9H-purin-9-yl]-2,3-dihydroxy bicyclo[3.1.0]hex-1-yl][methyl] diphosphoric acid monoester |
| NBMPR                  | S6-(4-nitrobenzyl)mercaptopurine riboside                                   |
| NF449                  | 4,4′,4″,4‴-[Carbonyl bisc(imino-5,1,3-benzenetriyl-bis(carbonylimino))tetraakis-1,3 benzenedisulfonic acid |
| PPADS                  | pyridoxal phosphate-6-azaphenyl-2,4-disulfonic acid                         |
| R-PIA                  | R-N6-(2-phenylisopropyl)adenosine                                          |
| SCH5826               | 1,7-(2-phenylethyl)-5-amino-2-(2-furyl)-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine |
Purinergic influence in the retina is mediated by the release of various endogenous ligands for P1 and P2 purinoceptors from neuronal and non-neuronal cells [44,45]. In the retina, ATP release was found from the pigment epithelium layer, ganglion cells, and also from Müller glia cells and astrocytes [13,46,47]. The presence of pannexin hemichannels and their contribution to ATP release have been demonstrated in the retina [35].

4.1. Heterogeneity of Purinoceptors

Purinergic receptors or purinoceptors are divided into nucleoside P1 and nucleotide P2 types based upon their natural ligands. P2 purinoceptors are further divided into two groups: P2X purinoceptors are ATP-gated ion channels, whereas P2Y purinoceptors are metabotropic and coupled to G proteins. P2 purinoceptors are sensitive to adenine and guanine nucleotides [2]. Released ATP activates P2X and several P2Y purinoceptor subtypes but other adenine or uridine nucleotides ADP, UTP, and UDP are also natural agonist ligands for some P2Y purinoceptor subtypes. P2Y purinoceptors consist of eight different subtypes designated as P2Y1,2,4,6,11,12,13,14. The downstream signal transduction linked to P2Y purinoceptors are mostly of two kinds, either Gq (P2Y1,2,4,6,11 receptors) or Gi (P2Y12,13,14) proteins are coupled to the receptors. Thus, P2Y purinoceptors with different signal transductions can evoke both excitation and inhibition. In addition, P2Y purinoceptors exhibit different agonist binding profiles: P2Y1, P2Y12, and P2Y13 purinoceptors are sensitive to adenine nucleotides; P2Y2 and P2Y4 are activated by adenine and uridine nucleotides; and human P2Y1 and P2Y6 purinoceptors are primarily affected by uridine nucleotides [23].

The response of Gq protein-coupled P2Y purinoceptors to ATP is an increase in intracellular inositol trisphosphate (IP3) level, a rapid transient release of Ca2+ from internal stores followed by an increase of intracellular Ca2+ concentration, and also a Ca2+ influx into the cells [34]. Illes and coworkers [48] proposed that this increase of intracellular Ca2+ concentrations results in opening K+ channels, allowing an outward-directed K+ current, and membrane hyperpolarization in microglial cells.

The P2X ionotropic purinoceptors are ligand-gated cationic channels and are non-selectively permeable to Na+, K+, and Ca2+. P2X purinoceptors have seven subtypes identified as P2X1 to P2X7 and are sensitive to ATP but not to ADP, AMP, and adenosine [4,23]. In response to ATP, P2X purinoceptors mediate fast excitatory neurotransmission as their activation induces an inward-directed cation current and cellular membrane depolarization [34,48]. P2X purinoceptors are also linked to Ca2+ signaling via receptor-coupled Ca2+-permeable cationic channels, allowing Ca2+ entry into the cells [24].

The other types of purinoceptors are the P1 type [46]. Adenosine is the natural ligand for P1 nucleoside receptors, which activates all four different receptor subtypes, A1, A2A, A2B, and A3. Adenosine receptors are only sensitive to the nucleoside adenosine [2] whereas Luongo and coworkers [26] reported that treatment with ATP upregulated adenosine A1 receptor expression in microglia. Adenosine receptors possess metabotropic signal transduction: A1 and A3 receptors are coupled to Gi proteins and A2A and A2B receptors are linked to Gs proteins. Accordingly, activation of adenosine receptors leads to stimulation or inhibition of adenylylate cyclase and to an increase or decrease of tissue cAMP levels. Activation of A1 receptors results in mostly opposite effects to A2A receptors. The P1 purinoceptor agonist adenosine fails to generate a [Ca2+]i response in cultured microglia indicating that ATP action on intracellular Ca2+ is mediated only through activation of P2 purinoceptors [24]. Inhibitory response of purinoceptors coupled to Gi proteins (A1 and A3 adenosine receptors and some P2Y purinoceptors) is a decrease in cAMP levels leading to Ca2+ and K+ channel dephosphorylation that results in membrane hyperpolarization [26].
4.2. Purinoceptors in the Retina

P2 purinoceptors possess distinct expression profiles in the retina. P2Y metabotropic receptors are expressed in neurons and glial cells and the retinal pigment epithelium [49]. P2Y1 purinoceptors may have a preferential expression in retinal macroglia including Müller glia cells, whereas P2Y12, P2Y13, and P2Y13 purinoceptors were identified in astroglial cells [50]. Increased purinergic activity induces gliosis in Müller glia cells as was demonstrated by increased GFAP immunoreactivity and the involvement of P2Y1 purinoceptor was suggested to evoke this effect [51]. Microglial cells in the retina express the P2Y1 purinoceptor subtype [51].

P2X purinoceptors are expressed on most classes of neurons in the retina. The presence of P2X receptor immunoreactivity in GABAergic amacrine cells supports previous findings that purinergic signals modulate information processing by GABAergic amacrine cells [49]. Other laboratories identified an abundant expression of P2X purinoceptors in the inner and outer plexiform layers, in ganglion cells, Müller glia cells, astrocytes, and microglia in high concentrations [23,52]. Wurm and coworkers [53] reported that, although P2X purinoceptors are expressed in human Müller cells, P2X purinoceptors are largely absent in other mammalian Müller glia cells. Depending on the receptor-coupled signal transduction, the effects mediated by P2X and P2Y receptors may be synergistic or antagonistic in retinal circuitry.

Similarly to P2 purinoceptors, P1 purinoceptors are present in retinal pigment epithelial cells and ganglion cells also express multiple adenosine receptors [49]. A1, A2A, and A3 adenosine receptor mRNAs were detected in the inner nuclear layer of the retina. A2A and A3 receptors are present in retinal pigment epithelial cells, Müller glia cells, and they are also expressed in microglia in the retina [2].

A1 receptors are inhibitory in nature and suppress excitatory neurotransmission [46]. Adenosine is a major inhibitor of neural activity in the retina. Increased production of adenosine in the extracellular space activates inhibitory A1 receptors and neuronal activity is decreased [13]. The A1 receptor agonist CPA decreased the number of apoptotic nuclei and GFAP immunoreactivity in the retina exposed to excessive light to induce neurodegeneration. This effect was reversed by the A1 receptor antagonist DPCPX [54].

4.3. Purinergic Regulation of Microglia

Microglia express P2Y and P2X purinoceptors in resting and activated states [4]. Further analysis demonstrated that the majority of microglial cells in proliferating (resting) state express P2X purinoceptors and non-proliferating (activated or alerted phenotype) microglial cells express both P2Y and P2X purinoceptors [48]. Färber and Kettenmann [34] reported the presence of all the eight different types of P2Y purinoceptors and six types of P2X purinoceptors (P2X1,2,3,4,6,7) in the microglial cell line. Accordingly, addition of ATP affects several metabotropic and ionotropic transduction systems in microglia [55,56].

ATP and adenosine alter the morphology of microglia by inducing an outgrowth of microglia processes. ATP also regulates the motility of microglial processes and elicits rapid chemotactic responses in the retina [7,57]. Microglial chemotaxis as a response to neuronal injury is regulated by P2Y12 receptors. Ogata and coworkers [56] reported that activation of P2Y receptors induces microglia proliferation and accelerates process retraction of the cells. Furthermore, P2Y1,3,4 receptors expressed on microglia regulate phagocytosis [58]. Uckermann and coworkers [21] also reported that rabbit retinal microglial cells contain P2Y1 receptors and their activation leads to microglial cell activation. In addition, P2X7 purinoceptors mediate chemotaxis, and P2X7 purinoceptors are involved in transformation of microglia to the proinflammatory phenotype [26]. Of the P1 purinoceptors, A1 and A2B adenosine receptors have been negatively implicated into the regulation of microglia morphology and responses, and proliferation and mediator release [11]. A2A receptor upregulation has a role in the regulation of extension and retraction of microglial processes [59].
LPS stimulated TNFα, IL-1β, and IL-6 release and ATP inhibited these effects in cultured microglia obtained from rat spinal cord. In addition, the P2Y2 purinoceptor agonist 2-MeSATP exerted similar inhibition [56]. It was shown that the P2Y2 and P2Y6 purinoceptor ligands UTP, UDP, and the hydrolysis-resistant ATP analogue ATPγS stimulated the basal and TNFα-induced secretion of the chemotactic factor IL-8 in human retinal pigment epithelium [60]. These observations raise the possibility that P2Y purinoceptors coupled to Gq or Gi proteins may oppositely regulate the production of proinflammatory cytokines from microglia.

Activation of different P2 receptors occurs at a temporal scale. First, ATP activates microglial P2X7-purinoceptors following an ischemic insult inducing an immediate tissue necrosis followed by activation of purinoceptors on astroglia cells and neurons [5]. In addition, ATP stimulates P2X7 purinoceptors at millimolar concentration, whereas P2Y purinoceptors can be activated in a 10–100 μmol concentration range of ATP [56]. P2X7 purinoceptors exhibit a low sensitivity to ATP resulting in activation only in pathological conditions (tissue damage, neuroinflammation, mechanical stress or injury, trauma, hypoxia, or ischemia) when extracellular ATP concentrations reach high levels.

ATP-activated P2X7 purinoceptors are also principal regulators of neuroinflammatory responses. P2X7 purinoceptor activation induces IL-1β release from macrophages and ADP and AMP also act as promoters of LPS-induced IL-1β secretion in microglia cells [36]. P2X7 receptor mediates cytokine release from microglia [52]. A series of studies demonstrated that P2X7 receptor stimulation of immune cells by ATP evokes release of the proinflammatory TNFα and IL-1β from mouse or rat microglial cell lines [61]. This release of TNFα was found to be dependent upon Ca2+ influx and MAP kinase cascade activation [62]. In contrast, Shigemito-Mogami and coworkers [63] reported that the production of the proinflammatory cytokine IL-6 was under the control of P2Y rather than P2X purinoceptors in mouse microglial cell lines.

The production and release of proinflammatory cytokines seem to be oppositely regulated by the metabotropic P2Y and the ionotropic P2X receptors in microglial cells [4]. The apparently opposite effects of P2X and P2Y purinoceptors on proinflammatory factors may be explained by the different signal transduction systems utilized by these receptors. Ogata and coworkers [56] also found opposite effects of P2X (stimulation) and P2Y purinoceptor (inhibition) on TNFα release from cultured spinal cord microglia.

Microglial cells express all subtypes of P1 purinoceptors, A1, A2A/B, and A3 [11]. The various types of adenosine receptors also exhibit different sensitivity to their natural ligand adenosine [39]. Gi protein-coupled A1 adenosine receptor stimulation decreases and Gs protein-coupled A2A receptors stimulation exerts an opposite effect on microglia activity (Table 2). The A1 receptor agonist CPA inhibited TNFα and GFAP mRNA expression and the A1 receptor antagonist DPCPX caused an opposite effect on GFAP immunoreactivity in the retina [54]. CPA also lowered TNFα mRNA expression in light-induced retinal degeneration in rats. Activation of A1 adenosine receptors inhibited LPS-induced TNFα release in activated retinal microglial cells [2]. Madeira and coworkers [64] reported that blockade of A2A receptor prevents retinal microglia activation and inflammatory responses in the retina. On the contrary, the A2A receptor agonist CGS21680 decreased TNFα release in diabetic retina. CGS21680 also attenuated the expression of inflammatory IL-6 and TNFα. Suppression of the inflammatory cascade C-Raf/ERK by A2A receptor activation may be involved in the latter effect in microglia [2]. Ahmad and coworkers [65] also reported that activation of A2A adenosine receptors attenuated the hypoxia- or LPS-induced TNFα release. At present, conflicting reports can be found in the literature indicating that both stimulation and blockade of A2A receptors regulate the release of microglial proinflammatory bioactive proteins in the same direction [11,39,66]. The A1 receptor agonist CF101 exerts anti-inflammatory effects and inhibits proinflammatory cytokine release (TNFα, IL-6, IL-12). Downregulation of the NF-κB signaling pathway was suggested to be involved in the mechanism of CF101 [2].
Table 2. Purinoceptors, their signal transductions and endogenous ligands.

| Receptor                  | Signal Transduction       | Ligands                      |
|---------------------------|---------------------------|------------------------------|
| P2Y nucleotide purinoceptors |                           |                              |
| P2Y purinoceptors subtypes |                           |                              |
| P2Y1,2,4,6,11*             | G protein-coupled         | ATP, ADP and/or UTP, UDP     |
| P2Y purinoceptors subtypes |                           |                              |
| P2Y12,13,14                | G protein-coupled         | ADP, UDP                     |
| P2X nucleotide purinoceptors |                        |                              |
| P2X1,2,3,4,5,6             | cationic ion channel-coupled | ATP                          |
| P1 nucleoside purinoceptors |                          |                              |
| A1 adenosine receptor      | G protein-coupled         | adenosine                    |
| A2A, A3 adenosine receptor | G protein-coupled         | adenosine                    |
| A1 adenosine receptor      | G protein-coupled         | adenosine                    |

P2Y1,2,13 purinoceptors are sensitive to adenine nucleotides, P2Y2,4 purinoceptors are activated by adenine and uridine nucleotides, human P2Y4,6 are affected primarily by uridine nucleotides [4,23]. P2Y11 purinoceptors also mediate stimulation of adenyl cyclase activation. Increased cAMP may mobilize intracellular Ca2+ via activation of PLC-epsilon [67,68].

5. Glycinergic Transmission in the Retina

Glycine is an inhibitory neurotransmitter that exerts inhibition on various neurons by acting on strychnine-sensitive glycine receptors (GlyRs) in the retina. All the α1-4 sub-units of GlyRs were identified in the mammalian retina [69]. Glycine also has a mandatory coagonist role in activation of glutamate N-methyl-D-aspartate (NMDA) receptors both in the central nervous system and in the retina [70–72].

The neural circuit of the retina contains two kinds of glycinergic interneurons. Amacrine cells in the inner nuclear layer are synapsed with the cone pathway and establish feedback inhibition of bipolar cells thereby inhibiting responses of ganglion cells to light [73]. About half of the amacrine cells are glycinergic and they form in- and output innervations with bipolar cells, ganglion cells, and other amacrine cells [74]. Glycinergic amacrine cells synapse primarily with OFF bipolar cells [75] (Figure 1B). The other type of interneuron, which operates with glycine as a neurotransmitter, is the AII amacrine cells [8,76]. These interneurons transfer the light signal from rod bipolar cells to the cone pathways. Of the retinal glial cells, Müller cells and astrocytes are the potential sources of glycine. The cellular location of glycine in the retina indicates that it serves as a neurotransmitter in neurons and a gliotransmitter in glia cells and also participates in microglia activation [77].

The release of glycine from interneurons and macroglia cells occurs with vesicular exocytosis or reverse-mode operation of glycine transporter 1 (GlyT-1). Following neuronal release, glycine may reach the extrasynaptic space by spillover mechanism and affects extrasynaptic GlyR and NMDA receptor activities. In the vicinity of these receptors, glycine concentration is determined by GlyT-1 both in the synaptic and extrasynaptic space of the retina [78]. GlyT-1 is primarily localized to glial cells (Table 3), whereas GlyT-2, which is responsible for refilling presynaptic vesicles with glycine, is absent in the retina [79,80], but see Pena-Rangel et al. [81].
Of the macroglia cells, glycine is released from both Müller glia cells and astrocytes in the retina. In energy shortage conditions, declining cellular ATP levels cause failure of ion Na⁺/K⁺-ATPase ion pump operation and as a result intracellular Na⁺ concentration is elevated [1]. This altered ionic milieu favors shifting the operation of both glycine and glutamate transporters into the reverse mode [82]. The consequence of transporter reversal is an increased release of the amino acid neurotransmitters glycine and glutamate as was shown in isolated rat hippocampus and retina as well [15,78]. In response to hypoxia and cellular energy failure, ATP is also released from neuronal or glial sources, although the mechanism of this release differs from that of glutamate or glycine [35].

5.1. Heterogeneity of NMDA Receptors in the Retina

The ionotropic glutamate NMDA receptors, on which glycine acts as a mandatory coagonist, exhibit uneven distribution in the retina: A great number of NMDA receptors can be found in the ganglion cell layer [9,83]. NMDA receptors are expressed in retinal ganglion cells with different subunit compositions: NR1/NR2B NMDA receptors were found on ON ganglion cells in higher density, whereas the presence of NR1/NR2A NMDA receptors was demonstrated both in ON and OFF ganglion cell dendrites [84]. NR1/NR2A receptors are believed to be localized synthaptically and extrasynaptically NMDA receptors are primarily composed of NR1NR2B subunits [85]. NR1/NR2A and NR1/NR2B receptors possess different coagonists, D-serine and glycine, respectively [86]. D-Serine may be released from stressed Müller glia cells and astrocytes to potentiate the agonist effect of glutamate on synaptic NMDA receptors [87]. On the other hand, extrasynaptic glycine potentiates the effect of glutamate on extrasynaptic NR1/NR2B NMDA receptors [88]. Glycine, after its release from synapses between amacrine cells and the OFF pathway neurons,diffuses into the extrasynaptic space and influences activity of extrasynaptic NR1/NR2B receptors primarily located on ON ganglion cells [75,89]. Extrasynaptic NR1/NR2B NMDA receptors, which exhibit higher glycine sensitivity, mediate ganglion cell death by activating pro-death intracellular signaling in retinal ischemia/hypoxia [90,91].

5.2. Glycinergic Regulation of Microglia

Glycine bears modulatory features on microglia and is able to influence their pro- and anti-inflammatory functions. Accordingly, Carmans and coworkers [92] reported that glycine activated macrophage functions and stimulated the production of TNFα and other proinflammatory mediators. This effect of glycine was not mediated by GlyRs but rather
by activation of the neutral amino acid transporter (NAAT) system. Glycine activates Na⁺-dependent NAAT leading to increases in intracellular Na⁺ concentrations, inducing membrane depolarization, and enhancement of Ca²⁺ signaling; these events are essential for the release of inflammatory modulators [93]. Increases in extracellular glycine concentrations in response to ischemia of the retina or brain tissues may be high enough to activate the NAAT system in macrophages or microglial cells.

Schilling and Eder [77] also reported GlyR- and GlyT-independent, but NAAT-dependent, glycine-mediated effects in mouse microglia. Metabolic activity of cultured microglia was increased in the presence of glycine, whereas it was suppressed in a glycine-free medium [22]. Glycine is also known to enhance LPS-induced nitric oxide and superoxide productions in microglial cells [93]. Furthermore, glycine enhanced ATP-induced intracellular Ca²⁺ transients in microglial cells and this effect was due to Na⁺-coupled NAAT operation [93]. These effects of glycine in microglia point to a depolarization-dependent Ca²⁺ signaling and an increased production of inflammatory mediators. Ca²⁺ signals may, however, be under the control of different signaling systems in microglia. As mentioned above, ATP enhances the glycine-evoked intracellular Ca²⁺ transients in microglial cells possibly via activation of P2X purinoceptors. It was shown by Raouf and coworkers [94] that ATP initiates inflammatory cascades by acting on surface P2X purinoceptors of microglial cells.

Others concluded, however, that glycine has an inhibitory effect on immune cells by reducing the production of proinflammatory cytokines. It has been reported that glycine decreased the production of TNFα and IL-1β in human monocytes and inhibited TNFα production in rat alveolar macrophages [95,96]. These effects of glycine may be mediated by GlyR-dependent mechanisms rather than the NAAT system. These findings indicate that glycine influences macrophages by both GlyR-dependent and GlyR-independent mechanisms.

Hayashi and coworkers [97] reported that transferred microglia- and microglia-conditioned medium potentiated NMDA receptor-mediated synaptic responses in cortical neurons. Analyses with HPLC methods revealed that glycine and serine present in microglia-conditioned medium may be responsible for potentiation of NMDA-induced currents. Released glycine accumulates around glutamatergic synapses and it may build up a concentration sufficient to induce NMDA receptor activity-mediated neurotoxicity. Further in this line, microglia, after activation, have been reported to induce NMDA receptor-mediated neurotoxicity and neuronal death [22].

In energy compromised conditions, when disruption of the balances between normal- and reverse-mode operation of GlyT-1 occurs, GlyT-1 inhibitors decrease extracellular glycine levels [15,78], i.e., this class of compounds may negatively influence microglial activity.

6. Neurodegenerative and Neuroinflammatory Disorders in the Retina

Of the various clinical appearances of retinopathies, hypoxia/ischemia, glaucoma, diabetic neuropathy, and age-related macular degeneration affect a great number of the population. While these disorders exhibit different symptoms, there are several common events in their pathogeneses. Retinal hypoxia as a persisting insult may induce enhanced purinergic signaling and glutamatergic-glycinergic neurotransmission. Activation of the two systems may lead to a sustained release of inflammatory mediators from activated microglia and the resulting chronic inflammatory environment may initiate or exacerbate retinal neurodegenerative disorders. Ganglion cell destruction can be detected in parallel with abnormally elevated activity of microglia in almost all neurodegenerative disorders of the retina.
6.1. Enhanced Purinergic Signaling in Neurodegenerative/Neuroinflammatory Disorders of the Retina

Purinergic signaling is activated in all neurodegenerative disorders of the retina. ATP is released in excess amount into the extracellular space in hypoxia, inflammation, oxidative stress, or nutrient starvation [4]. Ischemia-like conditions trigger ATP release from rat hippocampal slices and this release likely occurs from the ischemic retina as well [35,98]. Using an in vivo microdialysis technique, co-release of ATP and glutamate was demonstrated from the accumbens nucleus following traumatic injury in the rat and interaction of ATP and glutamate has been proposed [68]. In addition, the non-selective P2 purinoceptor antagonist PPADS and the selective P2X7 purinoceptor antagonist BBG inhibited oxygen and glucose deprivation-induced glutamate release in rat hippocampus [99]. These findings indicate that endogenous ATP, when its release is evoked in energy-compromised conditions, may exert a stimulatory influence on glutamate release. Oxygen-glucose deprivation also evokes glutamate release from isolated rat retina [15] and glutamate released in ischemic retina evokes Ca2+-independent ATP release and transporter-mediated adenosine release [100]. In these experiments, hypoxia was induced by elevated intraocular pressure in rat retina and elevated glutamate release activated purinergic signaling by releasing ATP from glial cells. Thus, a bidirectional facilitation may exist between purinergic signaling and glutamatergic neurotransmission in ischemic neural and retinal tissues.

Experimental observations suggest that purinergic signaling involves P2Y purinoceptors in the mediation of both neurodegenerative and neuroprotective processes. In mice, deletion of P2Y receptors from Müller glia and ganglion cells was associated with increased survival of amacrine cells following retinal ischemia reperfusion, whereas ischemic death of photoreceptor cells appeared to be more pronounced. P2Y purinoceptor activation likely increases cytosolic Ca2+-signaling during ischemia leading to neurodegeneration of amacrine cells [51]. Accordingly, P2Y purinoceptors may support survival of photoreceptors but result in death of amacrine cells. In the zebrafish retina, P2Y1 purinoceptor stimulation by ADP exerts neuroprotection of inner retinal neurons [38]. These findings raise the possibility that neurons express P2Y purinoceptors coupled to Gq or Gi proteins and the excitatory or inhibitory downstream signaling results in neurodegeneration or neuroprotection in the retina [5].

An increase in extracellular ATP concentration also evokes P2X7 purinoceptor stimulation, which opens receptor-coupled ion channels and cation influx into the cells. Activation of P2X7 purinoceptors, which ensures excess Ca2+ permeability in neurons, occurs in tissue damage, neuroinflammation, or mechanical stress. Elevated intraocular pressure is also accompanied by increased levels of ATP in the extracellular space [13]. Moreover, P2X7 purinoceptor activation induces release of TNFα and proinflammatory cytokines from microglia and may cause neuronal degeneration and cell death [34]. Stimulation of the P2X7 purinoceptor has a role in ischemic neurodegeneration in the retina and can modulate retinal ganglion cell destruction [52].

Increased adenosine tissue concentration was observed in rat retina following ligation of the central retinal artery [41]. This increase in tissue adenosine levels may be the consequence of increased ATP hydrolysis due to imbalance between energy supply and demand [1]. Adenosine produced from released ATP may contribute to the neuroprotective effect in ischemic retina [41]. Alternatively, energy deprivation provokes enhanced intracellular Na+ concentrations and equilibrative nucleoside transporter type-1 operating in the reverse-mode increases adenosine efflux [4]. Elevated extracellular adenosine may activate a series of P1 adenosine receptors expressed in retinal neurons or glial cells leading to a short-term antiischemic effect [42,101]. Accordingly, the A1 receptor agonist R-PIA reduced retinal damage induced by the raise in intraocular pressure and improved electroretinogram after ischemia in the rat eye [102]. On the other hand, the blockade of A1 receptors increases neurotoxicity caused by hypoxia/ischemia or glutamate [46]. Thus,
the Gi protein-coupled A1 receptor signal transduction can be considered as an endogenous neuroprotective system. This neuroprotective effect may be attributed to inhibition of neuronal Ca\(^{2+}\) uptake [39]. In addition, activation of the inhibitory A1 receptors by adenosine attenuates the release of excitatory amino acids and exerts neuroprotection during glutamatergic neurotoxicity [46].

A2A receptors, which are coupled to Gs proteins, facilitate glutamate release and also facilitate NMDA receptor function at postsynaptic levels [46]. Blockade of A2A receptors with selective antagonists protect ganglion cells in retinal ischemia [11,42,101]. In microglia, inhibition of A2A adenosine receptors reduces the inflammatory response in retinal pigment epithelium and also reduces photoreceptor cell death [64]. In addition, the adenosine A2A receptor antagonist SCH58261 prevented microglia-mediated neuroinflammation and induced neuroprotection in the retina [64]. However, a series of experiments is paradoxical: It has been reported that the A2A receptor agonist CGS21680, similarly to the receptor antagonist, decreased microglial activation and retinal cell death in a mouse traumatic optic neuropathy model [65], but see Santiago et al. [66].

6.2. Enhanced Glutamatergic–Glycinergic Tone in Neurodegenerative/Neuroinflammatory Disorders of the Retina

The concentration of glutamate, the principal neurotransmitter in the retina, is elevated in the vitreous body or aqueous humor following experimental retinal ischemia, optic nerve neuropathy, and also in glaucoma patients [103]. Increases in extracellular glutamate concentration facilitate glutamate uptake into Müller glia cells, leading to cellular swelling [100]. This finding points to the important role of glia cells in neurodegenerative disorders including excitotoxic injury of the retina [1,103]. In addition, NMDA receptors are overstimulated when extracellular glutamate concentration is increased and this increase plays a pivotal role in neurodegenerative disorders of the retina. The resulting cellular insults can be ameliorated by using various NMDA receptor antagonists [1,104], albeit their clinical usefulness is a subject of debate.

Increased glycine levels have also been demonstrated in neurodegenerative–neuroinflammatory disorders of the central nervous system (amyotrophic lateral sclerosis, multiple sclerosis) and also of the eye [92]. Elevated glycine concentrations were found in the vitreous body in ischemia following ophthalmic artery occlusion [105]. Exocytotic glycine release can also be demonstrated from glycineric amacrine cells and this release may be directed outward concerning the synaptic cleft by the spillover mechanism. Glycine may be released from Müller glia cells and astrocyte by reverse-mode operation of GlyT-1 [71].

In physiological conditions, the GlyT-1-mediated glycine uptake reduces the possibility of glycine/glutamate-induced neurotoxicity. In oxygen and glucose deprivation-induced neurotoxicity, a decrease in glycine uptake and an increase in glycine release were found to indicate a forced reverse-mode operation of GlyT-1 in rat retina [15]. Ischemic conditions evoke simultaneous increase in \(^{3}\)H\{glutamate and \(^{3}\)H\}glycine release in the retina ensuring excess availability of the agonist and co-agonist at NR1/NR2B-type NMDA receptors [15]. The coagonist role of glycine in NMDA receptor activation indicates that glycine concentrations determined by GlyT-1 may have a key role in neurodegenerative disorders of the retina [15,71].

6.3. Activated Microglial Cells in Neurodegenerative Disorders of the Retina

Elevated intraocular pressure, which results in hypoxia in the retina, elicits glaucomatous neuropathy characterized by damage of ganglion cell axons and gradual loss of ganglion cells [100,106]. Reactive microglia have been observed in the retina following increased ocular pressure [11]. Microglial cells are redistributed in the retina as they can be detected in close vicinity of ganglion cell soma and axons [10]. Activation of microglia is showed by the observed increases of TNF\(_{\alpha}\), IL-6, and IL-8 proinflammatory cytokines in aqueous humor obtained from glaucoma patients [11]. These findings indicate that a
neuroinflammatory component is present and plays a significant role in glaucomatous retinal neuropathy.

Retinal hypoxia may also be involved in the pathomechanism of diabetic neuropathy of the retina [51]. Tissue hypoxia may result from insufficient microvascular circulation in diabetic neuropathy, which is accompanied by neurodegenerative events in the neural network of the retina. Reactive microglia in diabetic retinopathy are hypertrophic and exhibit an amoeboid shape. The perivascular presence of reactive microglia can be detected in cluster formation in diabetic retina [7]. Increased cytokine levels (TNF, IL-1β, IL-6, and IL-8) have been reported in the vitreous fluid of the eye indicating the involvement of a chronic inflammatory process in diabetic retinopathy [3]. Microcirculatory failure also induces a release of VEGF in diabetic retinopathy [107].

In age-related macular degeneration, pathological changes can be found in the retinal pigment epithelium and loss of photoreceptors is a key finding [64]. Impairment of photoreceptor functions is a consequence of neovascularization as novel blood vessels are formed in the outer retina in the wet-form of this retinal pathology. In age-related macular degeneration, microglia are accumulated in the outer nuclear layer and the subretinal space and around drusen deposits. Choroidal neovascularization and degeneration of the retinal pigment epithelium and photoreceptors are further characteristics of this disorder. Microglia are enlarged and exhibit an amoeboid shape in the retinal pigment epithelium. Activated microglia induce secretion of the proinflammatory cytokine IL-1β and increased cytokine levels were reported in the aqueous humor [3]. In wet-form of age-related macular degeneration, hypoxia/ischemia induces expression of VEGF, which results in disruption of the blood–retinal barrier and retinal edema underlies the pathology of macular degeneration [31].

7. A Tripartite Interaction: Purinergic–Glycinergic Cross-Talk and Microglia Activation in Neurodegenerative–Neuroinflammatory Disorders of the Retina

We have hypothesized a tripartite interaction in the development of neuroinflammatory–neurodegenerative disorders of the retina with the participation of the purinergic signaling, glutamatergic–glycinergic neurotransmission, and activated microglial cells. This interaction may be synergistic or attenuative depending on whether the participating events strengthen or debilitate each other’s effects, creating positive or negative feedback regulation. Whether pathological changes reinforce or weaken the functions of the participants in the tripartite interaction may have importance in microglia activation. Thus, microglia in an M1-activated state may turn into a sustained activation and chronic inflammatory pathologies in the retina, whereas microglia turning into an M2 state induce neuroregeneration, remodeling, and neuronal repair [30].

Activation of the tripartite interaction may be triggered by anoxia/ischemia resulting from disturbances in retinal blood circulation [31,52]. Thromboembolic occlusion of the retinal artery or vein, microcirculatory abnormalities in diabetic neuropathy, increased intraocular pressure, pathological angiogenesis in age-related macular degeneration, or arteriosclerosis of arteries in the optic nerve head all lead to reduced arterial blood flow in the posterior eye [32,105,108]. These disturbances in blood circulation lead to cellular energy shortage, which is accompanied by increased release of ATP and the amino acid neurotransmitters glycine and glutamate from neuronal or glial sources. ATP, when released in response to hypoxia, stimulates P2X receptors expressed on resting microglial cells facilitating their transit to activated state and neuroinflammatory conditions develop. Microglial cell activation by purinergic signaling may result in a sustained pathological state as ATP evokes glutamate release and in turn glutamate stimulates further efflux of ATP [28]. Thus, there might be a self-strengthening regulation between ATP and glutamate release occurring in hypoxic conditions. Further in line with glutamate released from neurons or macroglia cells in high concentrations activates NMDA receptors leading to a condition when excitotoxicity may be triggered.
Hypoxic conditions, however, also evoke glycine release from neurons and astrocytes in the central nervous system and retina. High extracellular glycine concentration stimulates microglia activity and the glycine-induced proinflammatory cytokine release may be an additional factor in neuronal cell damage in retinal circuitry [34,100]. Moreover, high extracellular glycine levels ensure the required coagonist concentration for activation of NMDA receptors. Microglial glycine has been reported to participate in stimulation of NMDA receptors leading to the possibility that activated microglial cells evoke in part overactive NMDA receptor-induced neurodegeneration [22]. Thus, interaction among neurons, macroglia, and microglial cells in glycine release also forms a self-strengthening regulation, which may end up in neurodegeneration.

Besides these self-strengthening mechanisms, attenuative regulations can also be observed in the proposed tripartite interaction. Accordingly, activated microglia are altered in order to express purinoceptors of the P2Y type and their activation decreases the production and release of proinflammatory cytokines and progress of neuroinflammation may slow down [56]. Moreover, P2Y purinoceptors activated by ATP on astrocytes stimulate normal (uptake) mode of operation of GlyT-1 leading to a decrease of extracellular glycine concentrations [50]. Recognition of the coagonist role of glycine in glutamate-mediated NMDA receptor activation led to the conclusion that decreases in extracellular glycine concentration may actually result in NMDA receptor hypofunctionality and exert neuroprotection in retinal neurodegenerative disorders. This goal can also be reached by inhibition of the reverse-mode operation of GlyT-1 by its selective inhibitors [15,109]. As shown in Figure 2A, the GlyT-1 inhibitor ACPPB decreased the oxygen-glucose deprivation-induced [1H]glycine release in isolated rat retina and this effect was due to an inhibition of the reverse-mode operation of GlyT-1. Besides inhibition of the reverse mode operation of GlyT-1, stimulation of normal mode operation also leads to a decrease of extracellular glycine concentrations and consequently to inhibition of overactivated NMDA receptors.

Figure 2. Oxygen and glucose deprivation (OGD)-induced [1H]glycine release from rat retina. This release was reversed by addition of the GlyT-1 inhibitor ACPPB (A) and the P2 purinoceptor agonist ligand ATP (B). Posterior eyecups containing the retinae were prepared from male Wistar rats, loaded with 10 μCi [1H]glycine for 30 min, and perfused with Krebs-bicarbonate buffer aerated with 95% O2/5% CO2 gas mixture for 60 min; then 25 three-min fractions were collected. The perfusion rate was kept at 1 mL/min; [1H]Glycine in the collected fractions and the tissue at the end of superfusion was determined and expressed as kBq/g/3 min. To evoke [1H]glycine release, the eyecups were superfused with glucose-free Krebs-bicarbonate buffer saturated with 95% N2/5% CO2 gas mixture added from fraction 10 and maintained through the experiment. The GlyT-1 inhibitor ACPPB, (Merck 13-h, glycine uptake inhibition IC50 1.1 × 10^−6 mol/L, was determined in rat cerebral cortex synaptosomes) was added in a concentration of 10^−6 mol/L from fraction 5 and maintained through the experiment [110,111]. ACPPB was synthesized by Professor Dr. Peter Matyas, Semmelweis University, Budapest, Hungary. ATP was added in a concentration of 10^−6 mol/L from fraction 5 and maintained through the experiment. Data shown as mean±S.E.M., n = 3–4. For methodological details see Hanuska et al. [15].

Jiménez [50] and coworkers reported that the P2Y1,12,13 purinoceptor agonist 2-MeS-ADP stimulated the uptake (normal) mode operation of GlyT-1 in rat brainstem primary
neuronal cultures. This effect was partially reversed by the P2Y1 antagonist MRS2179, the P2Y13 antagonist MRS2211, and the non-selective P2 purinoceptor antagonist suramin (Table 1). This finding suggests the involvement of the Gq protein-coupled P2Y1 and Gi protein-coupled P2Y13 purinoceptors in the regulation of GlyT-1 activity with an apparent P2Y1 purinoceptor dominance. Thus, besides GlyT-1 inhibition, P2 purinoceptor stimulation may also decrease extracellular glycine concentrations by stimulation of the normal-mode operation of GlyT-1. As shown in Figure 2B, the non-selective P2 natural purinoceptor agonist ATP decreased the oxygen-glucose deprivation-induced [3H]glycine release from rat retina. While we consider our finding preliminary and in need of further confirmation using more selective receptor ligands, we speculated that ATP stimulating P2Y purinoceptors forces GlyT-1 operation into the uptake mode. The resulting decrease in extracellular glycine concentrations may then prevent overactivation of NMDA receptors and thereby attenuate the exocytotic cascade. The biological substrate for the cross-talk between purinoceptors and GlyT-1 might be the astrocytes, which express P2 type purinoceptors as well as GlyT-1 immunoreactivity in the retina [68,79].

The third participant in this tripartite interaction is microglia. Concerning retinal pathologies, in which glutamatergic–glycinergic neurotransmission and ATP/adenosine-mediated signaling are functional, the presence of activated microglia has also been demonstrated. Induction of proinflammatory cytokine production may be deleterious to injured cells after ischemic insults as was shown in retinal vascular occlusion and reperfusion [112]. Microglial cells in the hypothesized tripartite interaction receive stimulation by glycine released in excess from neurons and astrocytes and by ATP and adenosine via P2X purinoceptors and stimulatory adenosine receptors. On the other hand, a number of experiments point to the inhibitory purinergic influence mediated by ATP and adenosine via P2Y purinoceptors and inhibitory adenosine receptors. The balance between stimulatory and inhibitory influences determines whether activated microglia are shifted to permanent neuroinflammation or remodeling and neuronal repair occur. The hypothesized tripartite interaction between glutamatergic–glycinergic neurotransmission, purinergic modulation, and microglia is shown in Figure 3.

**HYPOXIA/TISSUE INJURY**

![Diagram of Purinergic–glycinergic cross-talk and microglia activation in neurodegenerative–neuroinflammatory disorders in the retina: A hypothetical model. Impaired microcirculation evokes energy](image-url)
deficiency in the retina leading to increased release of glutamate from neurons or macroglial cells by vesicular exocytosis or reverse-mode operation of excitatory amino acid transporter (EAAT). Cellular energy deficiency also evokes increase in ATP efflux from neurons or glia cells by Ca\(^{2+}\)-dependent exocytosis or opening of pannexin hemichannels. There may be a self-strengthening interaction between glutamate and ATP: Glutamate induces ATP release and ATP efflux leads to an increase of glutamate release. In addition, glycine is released from energy-compromised neurons and macroglia by reverse operation of glycine transporter 1 (GlyT-1) in the retina. Excess release of glycine and glutamate overactivates extrasynaptic NR1/NR2 type NMDA receptors, which evokes neurotoxicity. In contrast, synaptic NR1/NR2A type NMDA receptors mediate neuroprotection. Increased glycine release induces further release of glycine from activated microglial cells by altering Ca\(^{2+}\) transients and shifts neutral amino acid transporter (NAAT) operation in reverse-mode. Glycine-induced glycine release from microglia, a self-strengthening interaction, facilitates glutamate-induced overstimulation of NMDA receptors, triggering exocytotoxicity. This mechanism can be an additional self-strengthening interaction: Glycine induces further release of glycine from activated microglial cells, which participates in extrasynaptic NMDA receptor overstimulation. The evoked NMDA receptor-mediated neurotoxicity primarily damages ON ganglion cells in the retina. Further in the interactions: ATP released by cellular energy deficiency stimulates GlyT-1 normal operation via activation of P2Y purinoceptors, which decreases extracellular glycine levels. GlyT-1 inhibitors inhibit pathological reverse-mode operation of GlyT-1. These two effects on GlyT-1 operation inhibit microglia activity by decreasing extracellular glycine concentrations. ATP released from stressed neurons and glia cells stimulates P2X and P2Y purinoceptors expressed in microglia, which induces stimulation or inhibition of the production and release of TNFα and proinflammatory cytokines (IL-1α, IL-1β, IL-6, IL-12). Adenosine produced by a breakdown of ATP or released from cells stimulates or inhibits microglia activity via adenosine receptors; the participating receptors with opposite effects are the inhibitory A₁ and A₃ and the stimulatory A₂₆ and A₂₅ adenosine receptors. The balance of this tripartite interaction may either be shifted to a neurodegenerative–neuroinflammatory direction or lead to neuroprotection serving inflammation resolution and neuronal survival.

8. Conclusions: Possible Therapeutic Consequences

The tripartite interaction between purinergic modulation, glutamatergic–glycinergic neurotransmission, and microglia activation provides three therapeutic target pathways in neuroinflammatory–neurodegenerative disorders of the retina. First, GlyT-1 inhibitors [16,113] block reverse-mode operation of the transporter in pathological conditions and decrease the concentrations of the coagonist glycine at NR1/NR2B-type NMDA receptors. These effects of GlyT-1 inhibitors may lead to protection of retina ganglion cells. Moreover, decreased extracellular glycine concentrations may also lead to decreased microglia activity with therapeutic consequences.

Second, P2Y purinoceptor agonists and P2X purinoceptor antagonists inhibit microglial activity and decrease the production and release of TNFα and other proinflammatory biological substances. Thus, modulation of microglial reactivity by P2Y agonists and P2X antagonists has emerged as a possible therapeutic intervention to maintain neurodegenerative courses at a low level. A similar effect might be expected from A₁: adenosine receptor agonists and A₃: adenosine receptor antagonists [43].

Third, microglia activation inhibited by minocycline may suppress the damage of retinal ganglion cells in ischemia and glaucoma [114]. Moreover, decreasing circulated VEGF released from microglia or blockade of VEGF receptor may slow down exacerbation of choroidal neovascularization with a beneficial influence on retina functions in diabetic retinopathy and wet-form of retina macular degeneration [7,31].

Author Contributions: Conceptualization, L.K. and L.G.H.J.; data curation, L.G.H.J., L.K., and T.Z.; writing—original draft preparation, L.G.H.J.; writing—review and editing, L.K., L.G.H.J., G.S., T.Z.; visualization, L.G.H.J., G.S.; funding acquisition, L.K. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the Higher Education Institutional Excellence Program of the Ministry of Human Capacities in Hungary, within the framework of the Neurology thematic program of Semmelweis University (FIKP 2020).
Institutional Review Board Statement: Not applicable.
Informed Consent Statement: Not applicable.
Data Availability Statement: Not applicable.
Acknowledgments: The support of the Higher Education Institutional Excellence Program of the Ministry of Human Capacities in Hungary is greatly acknowledged.
Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

- ATP: adenosine triphosphate
- GFAP: glial fibrillary acidic protein
- GlyR: glycine receptor
- GlyT-1: glycine transporter-1
- IL: interleukin
- IP3: inositol trisphosphate
- LPS: lipopolysaccharide
- NMDA: N-methyl-D-aspartate
- NAAT: neutral amino acid transporter
- TNFα: tumor necrosis factor α
- VEGF: vascular endothelial growth factor

References

1. Osborne, N.N.; Casson, R.J.; Wood, J.P.; Chidlow, G.; Graham, M.; Melena, J. Retinal ischemia: Mechanisms of damage and potential therapeutic strategies. *Prog. Retin. Eye Res.* 2004, 23, 91–147, doi:10.1016/j.preteyeres.2003.12.001.
2. Guzman-Aranguez, A.; Gasull, X.; Diebold, Y.; Pintor, J. Purinergic receptors in ocular inflammation. *Mediat. Inflamm.* 2014, 2014, 329096, doi:10.1155/2014/329096.
3. Rashid, K.; Akhtar-Schaefer, I.; Langmann, T. Microglia in Retinal Degeneration. *Front. Immunol.* 2019, 10, 1975, doi:10.3389/fimmu.2019.01975.
4. Sperlágh, B. ATP-Mediated Signaling in the Nervous System. In *Handbook of Neurochemistry and Molecular Neurobiology: Neurotransmitter Systems*; Lajtha, A., Vizi, E.S., Eds.; Springer: Boston, MA, USA, 2008; pp. 227–254.
5. Illes, P.; Verkhratsky, A.; Burnstock, G.; Sperlágh, B. Purines in neurodegeneration and neuroregeneration. *Neuropharmacology* 2016, 104, 1–3, doi:10.1016/j.neuropharm.2016.01.020.
6. Sterling, P.D., J.B. Retina. In *The Synaptic Organization of the Brain*, Shepherd, G.M., Ed.; Oxford University Press: Oxford, UK, 2004; pp. 217–270.
7. Madeira, M.H.; Boia, R.; Santos, P.F.; Ambrosio, A.F.; Santiago, A.R. Contribution of microglia-mediated neuroinflammation to retinal degenerative diseases. *Mediat. Inflamm.* 2015, 2015, 673090, doi:10.1155/2015/673090.
8. Nelson, R.F. Glycinergic neurons process images. *J. Physiol.* 2012, 590, 239–240, doi:10.1113/jphysiol.2011.224584.
9. Hama, Y.; Katsuki, H.; Tochikawa, Y.; Suminaka, C.; Kume, T.; Akaike, A. Contribution of endogenous glycine site NMDA agonists to excitotoxic retinal damage in vivo. *Neurosci. Res.* 2006, 56, 279–285, doi:10.1016/j.neures.2006.07.008.
10. Ramirez, A.I.; de Hoz, R.; Salobrar-Garcia, E.; Salazar, J.J.; Rojas, B.; Ajoy, D.; Lopez-Cuenca, I.; Rojas, P.; Trivino, A.; Ramirez, J.M. The Role of Microglia in Retinal Neurodegeneration: Alzheimer’s Disease, Parkinson, and Glaucoma. *Front. Aging Neurosci.* 2017, 9, 214, doi:10.3389/fnagi.2017.00214.
11. Santiago, A.R.; Baptista, F.I.; Santos, P.F.; Cristovao, G.; Ambrosio, A.F.; Cunha, R.A.; Gomes, C.A. Role of microglia adenosine A2(A) receptors in retinal and brain neurodegenerative diseases. *Mediat. Inflamm.* 2014, 2014, 465694, doi:10.1155/2014/465694.
12. Bringmann, A.; Pannicke, T.; Grosche, J.; Francke, M.; Wiedemann, P.; Skatchkov, S.N.; Osborne, N.N.; Reichenbach, A. Muller cells in the healthy and diseased retina. *Prog. Retin. Eye Res.* 2006, 25, 397–424, doi:10.1016/j.preteyeres.2006.05.003.
13. Reichenbach, A.; Bringmann, A. Purinergic signaling in retinal degeneration and regeneration. *Neuropharmacology* 2016, 104, 194–211, doi:10.1016/j.neuropharm.2015.05.005.
14. Gadea, A.; Lopez, E.; Lopez-Colome, A.M. Characterization of glycine transport in cultured Muller glial cells from the retina. *Glia* 1999, 26, 273–279, doi:10.1002/(sici)1098-1136(199906)26:4<273::aid-glia1>3.0.co;2-z.
15. Hanuska, A.; Szenasi, G.; Albert, M.; Koles, L.; Varga, A.; Szabo, A.; Matyus, P.; Harsing, L.G., Jr. Some Operational Characteristics of Glycine Release in Rat Retina: The Role of Reverse Mode Operation of Glycine Transporter Type-1 (GlyT-1) in Ischemic Conditions. *Neurochem. Res.* 2016, 41, 73–85, doi:10.1007/s11064-015-1713-z.
16. Harsing, L.G., Jr.; Juranyi, Z.; Gacsalyi, I.; Tapoleansy, P.; Czomp, A.; Matyus, P. Glycine transporter type-1 and its inhibitors. *Curr. Med. Chem.* 2006, 13, 1017–1044, doi:10.2174/092986706776360932.
17. Van den Eynden, J.; Ali, S.S.; Horwood, N.; Carmans, S.; Brone, B.; Hellings, N.; Steels, P.; Harvey, R.J.; Rigo, J.M. Glycine and glycine receptor signalling in non-neuronal cells. Front. Mol. Neurosci. 2009, 2, 9, doi:10.3389/neuro.02.009.2009.

18. Cantaut-Belarif, Y.; Antri, M.; Pizzarelli, R.; Colasse, S.; Vaccari, I.; Soares, S.; Renner, M.; Dalle, R.; Triller, A.; Bessis, A. Microglia control the glcyergic but not the GABAergic synapses via prostaglandin E2 in the spinal cord. J. Cell Biol. 2017, 216, 2979–2989, doi:10.1083/jcb.201607048.

19. Zhang, C.; Lam, T.T.; Tso, M.O. Heterogeneous populations of microglia/macrophages in the retina and their activation after retinal ischemia and reperfusion injury. Exp. Eye Res. 2005, 81, 700–709, doi:10.1016/j.exer.2005.04.008.

20. Okunuki, Y.; Mukai, R.; Nakao, T.; Tabor, S.J.; Butovsky, O.; Dana, R.; Ksander, B.R.; Connor, K.M. Retinal microglia initiate neuroinflammation in ocular autoimmunity. Proc. Natl. Acad. Sci. USA 2019, 116, 9989–9997, doi:10.1073/pnas.1820387116.

21. Uckermann, O.; Uhlmann, S.; Wurm, A.; Reichenbach, A.; Wiedemann, P.; Brüning, M. ADPβR evokes microglia activation in the rabbit retina in vivo. Purinergic Signal. 2005, 1, 383–387, doi:10.1007/s11302-005-0779-5.

22. Tanaka, J.; Toku, K.; Matsuda, S.; Sudo, S.; Fujita, H.; Sakanaoka, M.; Maeda, N. Induction of resting microglia in culture medium devoid of glycine and serine. Glia 1998, 24, 198–215.

23. Beamer, E.; Golonec, F.; Horvath, G.; Beko, K.; Otrokoczi, L.; Kovanyi, B.; Sperlagh, B. Purinergic mechanisms in neuroinflammation: An update from molecules to behavior. Neuropearmacology 2016, 104, 94–104, doi:10.1086/648879.

24. Moller, T.; Kann, O.; Verkhratsky, A.; Kettenmann, H. Activation of mouse microglial cells affects P2 receptor signaling. Brain Res. 2000, 853, 49–59, doi:10.1016/s0006-8993(99)02244-1.

25. Zhou, T.; Huang, Z.; Sun, X.; Zhu, X.; Zhou, L.; Li, M.; Cheng, B.; Liu, X.; He, C. Microglia Polarization with M1/M2 Phenotype Changes in rd1 Mouse Model of Retinal Degeneration. Front. Neuroanat. 2017, 11, 77, doi:10.3389/fnana.2017.00077.

26. Luongo, L.; Guida, F.; Imperatore, R.; Napolitano, F.; Gatta, L.; Cristino, L.; Giordano, C.; Siniscalco, D.; Di Marco, V.; Bellini, G.; et al. The A1 adenosine receptor as new player in microglia physiology. Glia 2014, 62, 122–132, doi:10.1002/glia.22592.

27. Viviani, B.; Corsini, E.; Galli, C.L.; Marinovich, M. Glia increase degeneration of hippocampal neurons through release of tumor necrosis factor-alpha. Toxicol. Appl. Pharmacol. 1998, 150, 271–276, doi:10.1006/tapp.1998.8406.

28. Eyo, U.B.; Peng, J.; Swiatkowski, P.; Mukherjee, A.; Bispo, A.; Wu, L.J. Neuronal hyperactivity recruits microglial processes via neuronal NMDA receptors and microglial P2Y12 receptors after status epilepticus. J. Neurosci. 2014, 34, 10528–10540, doi:10.1523/JNEUROSCI.0416-14.2014.

29. Miron, V.E.; Boyd, A.; Zhao, J.W.; Yuen, T.J.; Ruckh, J.M.; Shadrach, J.L.; van Wijngaarden, P.; Wagers, A.J.; Williams, A.; Franklin, R.J.M.; et al. M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination. Nat. Neurosci. 2013, 16, 1211–1218, doi:10.1038/nn.3469.

30. Cherry, J.D.; Olschowka, J.A.; O’Brien, M.K. Neuroinflammation and M2 microglia: The good, the bad, and the inflamed. J. Neuroinflamm. 2014, 11, 98, doi:10.1186/1742-2094-11-98.

31. Kaur, C.; Foulds, W.S.; Ling, E.A. Hypoxia-ischemia and retinal ganglion cell damage. Clin. Ophthalmol. 2008, 2, 879–889, doi:10.2147/oph.th.3361.

32. Whiteup, S.M.; Nussenblatt, R.B.; Lightman, S.L.; Hollander, D.A. Inflammation in retinal disease. Int. J. Inflam. 2013, 2013, 724648, doi:10.1155/2013/724648.

33. Frade, J.M.; Barde, Y.A. Microglia-derived nerve growth factor causes cell death in the developing retina. Neuron 1998, 20, 35–41, doi:10.1016/s0896-6771(98)00432-8.

34. Farber, K.; Kettenmann, H. Purinergic signaling and microglia. Pfuglers Arch. 2006, 452, 615–621, doi:10.1007/s00424-006-0064-7.

35. Reigada, D.; Lu, W.; Zhang, M.; Mitchell, C.H. Elevated pressure triggers a physiological release of ATP from the retina: Possible role for pannexin hemichannels. Neuroscience 1998, 157, 396–404, doi:10.1016/j.neuroscience.2008.08.036.

36. Silverman, W.R.; de Rivero Vaccari, J.P.; Locovei, S.; Qui, F.; Carlsson, S.K.; Scemes, E.; Keane, R.W.; Dahl, G. The pannexin 1 channel activates the inflammasome in neurons and astrocytes. J. Biol. Chem. 2009, 284, 18143–18151, doi:10.1074/jbc.M109.048084.

37. Sperlagh, B.; Szabo, G.; Erdelyi, F.; Baranyi, M.; Vizi, E.S. Homo- and heteroexchange of adenine nucleotides and nucleosides in rat hippocampal slices by the nucleoside transport system. Br. J. Pharmacol. 2003, 139, 623–633, doi:10.1016/s0007-0570(03)00428-5.

38. Battista, A.G.; Ricatti, M.J.; Pafundo, D.E.; Gautier, M.A.; Faillace, M.P. Extracellular ADP regulates lesion-induced in vivo cell proliferation and death in the zebrafish retina. J. Neurochem. 2009, 111, 600–613, doi:10.1111/j.1471-4159.2009.06352.x.

39. Latini, S.; Pedata, F. Adenosine in the central nervous system: Release mechanisms and extracellular concentrations. J. Neurochem. 2001, 79, 463–484, doi:10.1046/j.1471-4159.2001.06076.x.

40. Molina-Arcas, M.; Casado, F.J.; Pastor-Anglada, M. Nucleoside transporter proteins. Curr. Vasc. Pharmacol. 2009, 7, 426–434, doi:10.2174/157016109789043892.

41. Roth, S.; Rosenbaum, P.S.; Osniski, J.; Park, S.S.; Toledano, A.Y.; Li, B.; Moshfeghi, A.A. Ischemia induces significant changes in purine nucleoside concentration in the retina-choroid in rats. Exp. Eye Res. 1997, 65, 771–779, doi:10.1016/exer.1997.0391.

42. Ghirardi, G.J.; Gidday, J.M.; Roth, S. The purine nucleoside adenosine in retinal ischemia-reperfusion injury. Vis. Res. 1999, 39, 2519–2535, doi:10.1016/s0042-6989(99)00038-3.

43. Jacobson, K.A.; Civan, M.M. Ocular Purine Receptors as Drug Targets in the Eye. J. Ocul. Pharmacol. Ther. 2016, 32, 534–547, doi:10.1089/jop.2016.0090.

44. Housley, G.D.; Bringmann, M.; Reichenbach, A. Purinergic signaling in special senses. Trends Neurosci. 2009, 32, 128–141, doi:10.1016/j.tins.2009.01.001.
45. Wurm, A.; Erdmann, I.; Brügmann, A.; Reichenbach, A.; Pannicke, T. Expression and function of P2Y receptors on Muller cells of the postnatal rat retina. *Glia* **2009**, *57*, 1680–1690, doi:10.1002/glia.20883.

46. Cunha, R.A. Adenosine Neuromodulation and Neuroprotection. In *Handbook of Neurochemistry and Molecular Neurobiology: Neurotransmitter Systems*; Lahita, A., Vizi, E.S., Eds.; Springer: Boston, MA, USA, 2008; pp. 255–273.

47. Halassa, M.M.; Fellin, T.; Haydon, P.G. The tripartite synapse: Roles for glio transmission in health and disease. *Trends Mol. Med.* **2007**, *13*, 54–63, doi:10.1016/j.molmed.2006.12.005.

48. Illes, P.; Norens, W.; Gebicke-Haerter, P.J. Molecular mechanisms of microglial activation. B. Voltage- and purinoceptor-operated channels in microglia. *Neurochem. Int.* **1996**, *29*, 13–24, doi:10.1016/0197-0186(95)00133-6.

49. Sanderson, J.; Datt, D.A.; Trinkaus-Randall, V.; Pintor, J.; Civian, M.M.; Delamere, N.A.; Fletcher, E.L.; Salt, T.E.; Grosshe, A.; Mitchell, C.H. Purines in the eye: Recent evidence for the physiological and pathological role of purines in the RPE, retinal neurons, astrocytes, Muller cells, lens, trabecular meshwork, cornea and lacrimal gland. *Exp. Eye Res.* **2014**, *127*, 270–279, doi:10.1016/j.exer.2014.08.009.

50. Jimenez, E.; Zafra, F.; Perez-Sen, R.; Delicado, E.G.; Miras-Portugal, M.T.; Aragon, C.; Lopez-Corcuera, B. P2Y purinergic regulation of the glycine neurotransmitter transporters. *J. Biol. Chem.* **2011**, *286*, 10712–10724, doi:10.1074/jbc.M111.167056.

51. Pannicke, T.; Frommherz, I.; Biedermann, B.; Wagner, L.; Sauer, K.; Ulbricht, E.; Hartig, W.; Krugel, U.; Uebenham, U.; Arendt, T.; et al. Differential effects of P2Y1 deletion on glial activation and survival of photoreceptors and amacrine cells in the ischemic mouse retina. *Cell Death Dis.* **2014**, *5*, e1353, doi:10.1038/cddis.2014.317.

52. Niyadurupola, N.; Sidaway, P.; Ma, N.; Rhodes, J.D.; Broadway, D.C.; Sanderson, J. P2X7 receptor activation mediates retinal ganglion cell death in a human retina model of ischemic neurodegeneration. *Investig Ophthalmol. Vis. Sci.* **2013**, *54*, 2163–2170, doi:10.1167/iovs.12-10968.

53. Wurm, A.; Pannicke, T.; Landiev, I.; Francke, M.; Hohllorn, M.; Wiedemann, P.; Reichenbach, A.; Osborne, N.N.; Bringmann, A. Purinergic signaling involved in Muller cell function in the mammalian retina. *Prog. Retin. Eye Res.* **2011**, *30*, 324–342, doi:10.1016/j.preteyeres.2011.06.001.

54. Solino, M.; Lopez, E.M.; Rey-Funes, M.; Loidi, C.F.; Larrayoz, I.M.; Martinez, A.; Girardi, E.; Lopez-Costa, J.J. Adenosine A1 receptor: A neuroprotective target in light induced retinal degeneration. *PLoS ONE* **2018**, *13*, e0198838, doi:10.1371/journal.pone.0198838.

55. Wang, X.; Franciosi, S.; Bae, J.H.; Kim, S.U.; McLarnon, J.G. Expression of P2y and P2x receptors in cultured human microglia. *Proc. West. Pharmacol. Soc.* **1999**, *42*, 981.

56. Ogata, T.; Chuai, M.; Morino, T.; Yamamoto, H.; Nakamura, Y.; Schubert, P. Adenosine triphosphate inhibits cytokine release from lipopolysaccharide-activated microglia via P2y receptors. *Brain Res.* **2003**, *981*, 174–183, doi:10.1016/s0006-8993(03)00328-2.

57. Wang, M.; Wong, W.T. Microglia-Muller-cell interactions in the retina. *Adv. Exp. Med. Biol.* **2014**, *801*, 333–338, doi:10.1007/978-1-4614-3209-8_42.

58. Inoue, K. UDP facilitates microglial phagocytosis through P2Y6 receptors. *Cell Adhes. Migr.* **2007**, *1*, 131–132, doi:10.4161/cam.1.3.4937.

59. Orr, A.G.; Orr, A.L.; Li, X.J.; Gross, R.E.; Traynells, S.F. Adenosine A2A receptor mediates microglial process retraction. *Nat. Neurosci.* **2009**, *12*, 872–876, doi:10.1038/nn.2341.

60. Relvas, I.J.; Bouffioux, C.; Marcet, B.; Communi, D.; Makhou, M.; Horckmans, M.; Blero, D.; Bruyns, C.; Caspers, L.; Boeynaems, J.M.; et al. Extracellular nucleotides and interleukin-8 production by ARPE-19 cells: Potential role of danger signals in blood-retinal barrier activation. *Investig. Ophthalmol. Vis. Sci.* **2009**, *50*, 1241–1246, doi:10.1167/iovs.08-1902.

61. Ferrari, D.; Villalba, M.; Chiozzi, P.; Falzoni, S.; Ricciardi-Castagnoli, P.; Di Virgilio, F. Mouse microglial cells express a plasma membrane pore gated by extracellular ATP. *J. Immunol.* **1996**, 156, 1531–1539.

62. Hide, I.; Tanaka, M.; Inoue, A.; Nakajima, K.; Kohsaka, S.; Inoue, K.; Nakata, Y. Extracellular ATP triggers tumor necrosis factor-alpha release from rat microglia. *J. Neurochem.* **2000**, *75*, 965–972, doi:10.1046/j.1471-4159.2000.0750965.x.

63. Shigemoto-Mogami, Y.; Koizumi, S.; Tsuda, M.; Ohsawa, K.; Kohsaka, S.; Inoue, K. Mechanisms underlying extracellular ATP-evoked interleukin-6 release in mouse microglial cell line, MG-5. *J. Neurochem.* **2001**, *78*, 1339–1349, doi:10.1046/j.1471-4159.2001.00514.x.

64. Madeira, M.H.; Rashid, K.; Ambrosio, A.F.; Santiago, A.R.; Langmann, T. Blockade of microglial adenosine A2A receptor impacts inflammatory mechanisms, reduces ARPE-19 cell dysfunction and prevents photoreceptor loss in vitro. *Sci. Rep.* **2018**, *8*, 2272, doi:10.1038/s41598-018-20733-2.

65. Ahmad, S.; Fatteh, N.; El-Sherbini, N.M.; Naime, M.; Ibrahim, A.S.; El-Sherbini, A.M.; El-Shafey, S.A.; Khan, S.; Fulzele, S.; Gonzales, J.; et al. Potential role of A2A adenosine receptor in traumatic optic neuropathy. *J. Neuroimmunol.* **2013**, *264*, 54–64, doi:10.1016/j.jneuroim.2013.09.015.

66. Santiago, A.R.; Madeira, M.H.; Boia, R.; Aires, I.D.; Rodrigues-Neves, A.C.; Santos, P.F.; Ambrosio, A.F. Keep an eye on adenosine: Its role in retinal inflammation. *Pharmacol. Ther.* **2020**, *210*, 107513, doi:10.1016/j.pharmacthera.2020.107513.

67. Bucheimer, R.E.; Linden, J. Purinergic regulation of epithelial transport. *J. Physiol.* **2004**, *555*, 311–321, doi:10.1113/jphysiol.2003.056697.

68. Franke, H.; Krugel, U.; Illes, P. P2 receptors and neuronal injury. *Pflug. Arch.* **2006**, *452*, 622–644, doi:10.1007/s00424-006-0071-8.

69. Wassle, H.; Heinze, L.; Ivanova, E.; Majumdar, S.; Weiss, J.; Harvey, R.J.; Haverkamp, S. Glycinergic transmission in the Mammalian retina. *Front. Mol. Neurosci.* **2009**, *2*, 6, doi:10.3389/neuro.02.006.2009.
70. Johnson, J.W.; Ascher, P. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature 1987, 325, 529–531, doi:10.1038/325529a0.

71. Harsing, L.G., Jr.; Albert, M.; Matyus, P.; Szenasi, G. Inhibition of hypoxia-induced [{\textsuperscript{(3)H}}]glycine release from chicken retina by the glycine transporter type-1 (GlyT-1) inhibitors NFPS and Org-24461. Exp. Eye Res. 2012, 94, 6–12, doi:10.1016/j.exer.2011.10.010.

72. Eulenburg, V.; Knop, G.; Sedmak, T.; Schuster, S.; Hauf, K.; Schneider, J.; Feigenspan, A.; Joachimsthaler, A.; Brandstatter, J.H. GlyT1 determines the glycineric phenotype of amacrine cells in the mouse retina. Brain Struct. Funct. 2018, 223, 3251–3266, doi:10.1007/s00429-018-1684-3.

73. Masland, R.H. The fundamental plan of the retina. Nat. Neurosci. 2001, 4, 877–886, doi:10.1038/nn901-877.

74. Dumitrescu, O.N.; Protti, D.A.; Majumdar, S.; Zeilhofer, H.U.; Wasse, H. Iontropic glutamate receptors of amacrine cells of the mouse retina. Vis. Neurosci. 2006, 23, 79–90, doi:10.1017/S095252380621079.

75. Ivanova, E.; Muller, U.; Wasse, H. Characterization of the glycineric input to bipolar cells of the mouse retina. Eur. J. Neurosci. 2006, 23, 350–364, doi:10.1111/j.1460-9568.2005.05457.x.

76. Lee, E.-J.; Mann, L.B.; Rickman, D.W.; Lim, E.-J.; Chun, M.-H.; Grzywacz, N.M. All amacrine cells in the distal inner nuclear layer of the mouse retina. J. Comp. Neurol. 2006, 494, 651–662, doi:10.1002/cne.20838.

77. Schilling, T.; Eder, C. A novel physiological mechanism of glycine–induced immunomodulation: Nat−coupled amino acid transporter currents in cultured brain macrophages. J. Physiol. 2004, 559, 35–40, doi:10.1113/jphysiol.2004.070763.

78. Harsing, L.G., Jr.; Matyus, P. Mechanisms of glycine release, which build up synaptic and extrasynaptic glycine levels: The role of synaptic and non-synaptic glycine transporters. Brain Res. Bull. 2013, 93, 110–119, doi:10.1016/j.brainresbull.2012.12.002.

79. Zafra, F.; Aragon, C.; Olivares, L.; Danbolt, N.C.; Gimenez, C.; Storm-Mathis, J. Glycine transporters are differentially expressed among CNS cells. J. Neurosci. 1995, 15, 3952–3969.

80. Oyama, M.; Kuraoka, S.; Watanabe, S.; Iwai, T.; Tanabe, M. Electrophysiological evidence of increased glycine receptor-mediated phasic and tonic inhibition by blockade of glycine transporters in spinal superficial dorsal horn neurons of adult mice. J. Pharmacol. Sci. 2017, 133, 162–167, doi:10.1016/j.jphs.2017.02.011.

81. Pena-Rangel, M.T.; Riesgo-Escovar, J.R.; Sanchez-Chavez, G.; Salceda, R. Glycine transporters (glycine transporter 1 and glycine transporter 2) are expressed in retina. Neuroreport 2008, 19, 1295–1299, doi:10.1097/WNR.0b013e32830a9618.

82. Thomsen, C. Glycine transporter inhibitors as novel antipsychotics. Drug Discov. Today Ther. Strateg. 2006, 3, 539–545, doi:10.1016/j.ddstr.2006.10.016.

83. Fletcher, E.L.; Kalloniatis, M. Neurochemical architecture of the normal and degenerating rat retina. J. Comp. Neurol. 1996, 376, 343–360, doi:10.1002/(SICI)1096-9861(19961216)376:3<343::AID-CNE1>3.0.CO;2-2.

84. Kalbaugh, T.L.; Zhang, J.; Diamond, J.S. Coagonist release modulates NMDA receptor subtype contributions at synaptic inputs to retinal ganglion cells. J. Neurosci. 2009, 29, 1469–1479, doi:10.1523/JNEUROSCI.4240-08.2009.

85. Liu, Y.; Wong, T.P.; Aarts, M.; Rooyackers, A.; Liu, L.; Lai, T.W.; Wu, D.C.; Lu, J.; Tymianski, M.; Craig, A.M.; et al. NMDA receptor subunits have differential roles in mediating excitotoxic neuronal death both in vitro and in vivo. J. Neurosci. 2007, 27, 2846–2857, doi:10.1523/JNEUROSCI.0116-07.2007.

86. Papouin, T.; Ladepoeche, L.; Ruel, J.; Sacchi, S.; Labasque, M.; Hanini, M.; Groc, L.; Pollegioni, L.; Mothet, J.P.; Oliet, S.H. Synaptic and extrasynaptic NMDA receptor channels are gated by different endogenous coagonists. Cell 2012, 150, 633–646, doi:10.1016/j.cell.2012.06.029.

87. Stevens, E.R.; Esguerra, M.; Kim, P.M.; Newman, E.A.; Snyder, S.H.; Zahs, K.R.; Miller, R.F. D-serine and serine racemase are present in the vertebrate retina and contribute to the physiological activation of NMDA receptors. Proc. Natl. Acad. Sci. USA 2003, 100, 6789–6794, doi:10.1073/pnas.1237052100.

88. Reed, B.T.; Sullivan, S.J.; Tsai, G.; Coyle, J.T.; Esguerra, M.; Miller, R.F. The glycine transporter GlyT1 controls N-methyl-D-aspartic acid receptor coagonist occupancy in the retina. Eur. J. Neurosci. 2009, 30, 2308–2317, doi:10.1111/j.1460-9586.2009.07202.x.

89. Eggers, E.D.; Lukasiewicz, P.D. Multiple pathways of inhibition shape bipolar cell responses in the retina. Vis. Neurosci. 2011, 28, 95–108, doi:10.1017/S0952523810000209.

90. Hardingham, G.E.; Fukunaga, Y.; Bading, H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat. Neurosci. 2002, 5, 405–414, doi:10.1038/nn835.

91. Parsons, M.P.; Raymond, L.A. Extrasynaptic NMDA receptor involvement in central nervous system disorders. Neuron 2014, 82, 279–293, doi:10.1016/j.neuron.2014.03.030.

92. Carmans, S.; Hendriks, J.J.; Thewissen, K.; Van den Eynden, J.; Stinissen, P.; Rigo, J.M.; Hellings, N. The inhibitory neurotransmitter glycine modulates macrophage activity by activation of neutral amino acid transporters. J. Neurosci. Res. 2010, 88, 2420–2430, doi:10.1002/jnr.22395.

93. Van den Eynden, J.; Notelaers, K.; Brone, B.; Janssen, D.; Nelissen, K.; Sahebali, S.; Smolders, I.; Hellings, N.; Steels, P.; Rigo, J.M. Glycine enhances microglial intracellular calcium signaling. A role for sodium-coupled neutral amino acid transporters. Pflug. Arch. 2011, 461, 481–491, doi:10.1007/s00424-011-1093-0.

94. Raouf, R.; Chabot-Dore, A.J.; Ase, A.R.; Blais, D.; Seguela, P. Differential regulation of microglial P2X4 and P2X7 ATP receptors following LPS-induced activation. Neuropharmacology 2007, 53, 496–504, doi:10.1016/j.neuropharm.2007.06.010.
95. Spittler, A.; Reissner, C.M.; Oehler, R.; Gornikiewicz, A.; Gruenberger, T.; Manhart, N.; Brodowicz, T.; Mittlboeck, M.; Boltz-Nitulescu, G.; Roth, E. Immunomodulatory effects of glycine on LPS-treated monocytes: Reduced TNF-alpha production and accelerated IL-10 expression. FASEB J. 1999, 13, 563–571, doi:10.1096/fasebj.13.5.563.

96. Wheeler, M.D.; Thurman, R.G. Production of superoxide and TNF-alpha from alveolar macrophages is blunted by glycine. Am J. Physiol. 1999, 277, L952-959, doi:10.1152/ajplung.1999.277.5.595.

97. Hayashi, Y.; Ishibashi, H.; Hashimoto, K.; Nakaniishi, H. Potentiation of the NMDA receptor-mediated responses through the activation of the glycine site by microglia secreting soluble factors. Glia 2006, 53, 660–668, doi:10.1002/glia.20322.

98. Juranyi, Z.; Sperlagh, B.; Vizi, E.S. Involvement of P2 purinoceptors and the nitric oxide pathway in [3H]purine outflow evoked by short-term hypoxia and hypoglycemia in rat hippocampal slices. Brain Res. 1999, 823, 183–190, doi:10.1006/srbe.1999.8993(99)01169-5.

99. Sperlagh, B.; Zsilla, G.; Baranyi, M.; Illes, P.; Vizi, E.S. Purinergic modulation of glutamate release under ischemic-like conditions in the hippocampus. Neuroscience 2007, 149, 99–111, doi:10.1016/j.neuroscience.2007.07.035.

100. Uckermann, O.; Wolf, A.; Kutzera, F.; Kalisch, F.; Beck-Sickinger, A.G.; Wiedemann, P.; Reichenbach, A.; Bringmann, A. Glutamate release by neurons evokes a purinergic inhibitory mechanism of osmotic glial cell swelling in the rat retina: Activation by neuropeptide Y. J. Neurosci. Res. 2006, 83, 538–550, doi:10.1002/jnr.20760.

101. Larsen, L.G.; Vilstrup, M.; Andersen, N.M.; Maxwell, K.M.; Roth, S. Differing roles of adenosine receptor subtypes in retinal ischemia-reperfusion injury in the rat. Exp Eye Res 1999, 68, 9–17, doi:10.1006/exer.1998.0573.

102. Uckermann, O.; Wolf, A.; Kutzera, F.; Kalisch, F.; Beck-Sickinger, A.G.; Wiedemann, P.; Reichenbach, A.; Bringmann, A. Glutamate release by neurons evokes a purinergic inhibitory mechanism of osmotic glial cell swelling in the rat retina: Activation by neuropeptide Y. J. Neurosci. Res. 2006, 83, 538–550, doi:10.1002/jnr.20760.

103. Schmidt, K.G.; Bergert, H.; Funk, R.H. Neurodegenerative diseases of the retina and potential for protection and recovery. Curr. Neuropharmacol. 2008, 6, 164–178, doi:10.2174/156802606778249784.

104. Chidlow, G.; Wood, J.P.; Casson, R.J. Pharmacological neuroprotection for glaucoma. Drugs 2007, 67, 725–759, doi:10.2165/00003495-200767050-00006.

105. Watahake, Y.; Yagihashi, T.; Kezuka, J.; Muramatsu, D.; Usui, M.; Iwasaki, T. Glutamate levels in aqueous humor of patients with retinal artery occlusion. Retina 2006, 26, 432–436, doi:10.1097/000006982-200604000-00009.

106. Osborne, N.N.; Melen, J.; Chidlow, G.; Wood, J.P. A hypothesis to explain ganglion cell death caused by vascular insults at the optic nerve head: Possible implication for the treatment of glaucoma. Br. J. Ophthalmol. 2001, 85, 1252–1259, doi:10.1136/bjo.85.10.1252.

107. Ozawa, Y.; Kamo, S.; Nishimura, M.; Kato, T.; Ban, N.; Toda, N.; Okamoto, D.; Yuki, K.; Miyake, S.; Tsubota, K. Neuroinflammation and Neurodegenerative Disorders of the Retina. Endocrinol. Metab. Synd. 2013, 2, doi:10.4172/2161-1017.1000111.

108. Hayreh, S.S. Retinal and optic nerve head ischemic disorders and atherosclerosis: Role of serotonin. Prog. Retin. Eye Res. 1999, 18, 191–221, doi:10.1016/s1350-9462(99)00016-0.

109. Harsing, L.G.; Zsilla, G.; Matyus, P.; Nagy, K.M.; Marko, B.; Gyarmati, Z.; Timar, J. Interactions between glycine transporter type 1 (GlyT1) and some inhibitor molecules—Glycine transporter type 1 and its inhibitors (review). Acta Physiol. Hung. 2012, 99, 1–17, doi:10.1556/APHysiol.99.2012.1.1.

110. Lindsley, C.W.; Wolkenberg, S.E.; Kinney, G.G. Progress in the preparation and testing of glycine transporter type-1 (GlyT1) inhibitors. Curr. Top. Med. Chem. 2006, 6, 1883–1896, doi:10.2174/156802606778249784.

111. Harsing, L.G., Jr; Albert, M.; Mátys, P.; Szénási, G. Glycine transporter 1 inhibitors may exert neuroprotective effects in hypoxic retina. Intrinsic Activity. 2016, 4, (Suppl. 3): A4.19, doi:10.25006/IA4A4.19.

112. N. Hangat, M.; Yoshimura, N.; Yoshihata, M.; Yabuuchi, K.; Honda, Y. Interleukin-1 gene expression in transient retinal ischemia in the rat. Investig. Ophthalmol. Vis. Sci. 1995, 36, 571–578.

113. Porter, R.A.; Dawson, L.A. GlyT-1 Inhibitors: From Hits to Clinical Candidates. In Small Molecule Therapeutics for Schizophrenia; eds. Celane, S. and Poli, S., Topics in Medicinal Chemistry 13, Springer, 2015; pp. 51–99.

114. Cukras, C.A.; Petrou, P.; Chew, E.Y.; Meyerle, C.B.; Wong, W.T. Oral minocycline for the treatment of diabetic macular edema (DME): Results of a phase I/II clinical study. Investig. Ophthalmol. Vis. Sci. 2012, 53, 3865–3874, doi:10.1167/iovs.11-9413.